Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review
- PMID: 24126647
- DOI: 10.7326/0003-4819-159-8-201310150-00006
Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review
Abstract
Background: Nonhealing ulcers affect patient quality of life and impose a substantial financial burden on the health care system.
Purpose: To systematically evaluate benefits and harms of advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers.
Data sources: MEDLINE (1995 to June 2013), the Cochrane Library, and reference lists.
Study selection: English-language randomized trials reporting ulcer healing or time to complete healing in adults with nonhealing ulcers treated with advanced therapies.
Data extraction: Study characteristics, outcomes, adverse events, study quality, and strength of evidence were extracted by trained researchers and confirmed by the principal investigator.
Data synthesis: For diabetic ulcers, 35 trials (9 therapies) met eligibility criteria. There was moderate-strength evidence for improved healing with a biological skin equivalent (relative risk [RR], 1.58 [95% CI, 1.20 to 2.08]) and negative pressure wound therapy (RR, 1.49 [CI, 1.11 to 2.01]) compared with standard care and low-strength evidence for platelet-derived growth factors and silver cream compared with standard care. For venous ulcers, 20 trials (9 therapies) met eligibility criteria. There was moderate-strength evidence for improved healing with keratinocyte therapy (RR, 1.57 [CI, 1.16 to 2.11]) compared with standard care and low-strength evidence for biological dressing and a biological skin equivalent compared with standard care. One small trial of arterial ulcers reported improved healing with a biological skin equivalent compared with standard care. Overall, strength of evidence was low for ulcer healing and low or insufficient for time to complete healing.
Limitations: Only studies of products approved by the U.S. Food and Drug Administration were reviewed. Studies were predominantly of fair or poor quality. Few trials compared 2 advanced therapies.
Conclusion: Compared with standard care, some advanced wound care therapies may improve the proportion of ulcers healed and reduce time to healing, although evidence is limited.
Primary funding source: Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative.
Comment in
-
Advanced wound care therapies in non-healing lower extremity ulcers: high expectations, low evidence.Evid Based Med. 2014 Jun;19(3):91. doi: 10.1136/eb-2013-101650. Epub 2013 Dec 17. Evid Based Med. 2014. PMID: 24347199 No abstract available.
Similar articles
-
Dressings and topical agents for arterial leg ulcers.Cochrane Database Syst Rev. 2020 Jan 20;1(1):CD001836. doi: 10.1002/14651858.CD001836.pub4. Cochrane Database Syst Rev. 2020. PMID: 31978262 Free PMC article.
-
Honey as a topical treatment for wounds.Cochrane Database Syst Rev. 2008 Oct 8;(4):CD005083. doi: 10.1002/14651858.CD005083.pub2. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2013 Feb 28;(2):CD005083. doi: 10.1002/14651858.CD005083.pub3. PMID: 18843679 Updated. Review.
-
Dressings and topical agents for arterial leg ulcers.Cochrane Database Syst Rev. 2015 Jun 29;(6):CD001836. doi: 10.1002/14651858.CD001836.pub3. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2020 Jan 20;1:CD001836. doi: 10.1002/14651858.CD001836.pub4. PMID: 26121115 Updated. Review.
-
Comparative effectiveness of advanced wound dressings for patients with chronic venous leg ulcers: a systematic review.Wound Repair Regen. 2014 Mar-Apr;22(2):193-204. doi: 10.1111/wrr.12151. Wound Repair Regen. 2014. PMID: 24635169 Review.
-
Dressings and topical agents for arterial leg ulcers.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001836. doi: 10.1002/14651858.CD001836.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2015 Jun 29;(6):CD001836. doi: 10.1002/14651858.CD001836.pub3. PMID: 17253465 Updated. Review.
Cited by
-
Targeting Matrix Metalloproteinase-9 for Therapeutic Intervention in Diabetic Foot Ulcers.ACS Pharmacol Transl Sci. 2024 Jul 16;7(10):2901-2911. doi: 10.1021/acsptsci.4c00263. eCollection 2024 Oct 11. ACS Pharmacol Transl Sci. 2024. PMID: 39421656 Review.
-
Modelling wound area in studies of wound healing interventions.BMC Med Res Methodol. 2024 Sep 16;24(1):206. doi: 10.1186/s12874-024-02326-y. BMC Med Res Methodol. 2024. PMID: 39285279 Free PMC article.
-
Inflammasome modulation with P2X7 inhibitor A438079-loaded dressings for diabetic wound healing.Front Immunol. 2024 Feb 15;15:1340405. doi: 10.3389/fimmu.2024.1340405. eCollection 2024. Front Immunol. 2024. PMID: 38426101 Free PMC article.
-
The Potential of PIP3 in Enhancing Wound Healing.Int J Mol Sci. 2024 Feb 1;25(3):1780. doi: 10.3390/ijms25031780. Int J Mol Sci. 2024. PMID: 38339058 Free PMC article.
-
Tailoring the secretome composition of mesenchymal stem cells to augment specific functions of epidermal regeneration: an in vitro diabetic model.Front Med Technol. 2023 Jun 12;5:1194314. doi: 10.3389/fmedt.2023.1194314. eCollection 2023. Front Med Technol. 2023. PMID: 37378005 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous